| Literature DB >> 35241167 |
Mirtneh Akalu1,2, BhadraMurthy Vemulapati3, Takele Abayneh4, Teferi Degefa4, Getaw Deresse4, Esayas Gelaye4.
Abstract
BACKGROUND: Bovine Respiratory Disease (BRD) is a multifactorial and economically important illness of cattle. The current study was designed to characterize the major bacterial pathogens associated with BRD and determine the antibiotic susceptibility patterns of isolates. Samples were collected from 400 pneumonic cases of cattle.Entities:
Keywords: Antibiogram; Ethiopia; H; M. haemolytica; P. multocida; Serotype; somni
Year: 2022 PMID: 35241167 PMCID: PMC8895590 DOI: 10.1186/s13620-022-00210-z
Source DB: PubMed Journal: Ir Vet J ISSN: 0368-0762 Impact factor: 2.146
Fig. 1BRD infected lung of cattle showing pneumonic and hemorrhagic lesion (arrow)
Prevalence of the major bacterial pathogens associated with BRD
| Variables | Samples | Total | Chi-square | |||||
|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal swab ( | Pneumonic lung tissue ( | |||||||
| Prevalence (%) | Prevalence (%) | Prevalence (%) | ||||||
| Age | Calves | 125 | 111 (88.80) | 45 | 45 (100) | 170 (42.5) | 156 (91.76) | 0.00001 |
| Adult | 75 | 71 (94.67) | 155 | 149 (96.13) | 230 (57.5) | 220 (95.65) | ||
| Sex | Male | 86 | 72 (83.72) | 187 | 184 (98.39) | 273 (68.25) | 256 (93.77) | 0.00001 |
| Female | 114 | 110 (96.49) | 13 | 10 (76.92) | 127 (31.75 | 120 (94.49) | ||
| Breed | local | 183 | 166 (90.71) | 181 | 176 (97.24) | 364 (91.0) | 342 (93.96) | 0.869 |
| Cross | 17 | 16 (94.12) | 19 | 18 (94.74) | 36 (9.0) | 34 (94.44) | ||
| Body condition | poor | 70 | 68 (97.14) | 15 | 15 (100) | 85 (21.25) | 83 (97.65) | 0.00001 |
| moderate | 94 | 87 (92.55) | 23 | 22 (95.65) | 117 (29.25) | 109 (93.16) | ||
| Good | 36 | 27 (75.0) | 162 | 157 (96.91) | 198 (49.5) | 184 (92.93) | ||
n – Sample size
The prevalence of the major bacterial pathogens from calves and adult cattle
| Isolates | Calves | Adult cattle | Total | Chi-Square | ||
|---|---|---|---|---|---|---|
| Nasopharyngeal swab | Pneumonic lung | Nasopharyngeal swab | Pneumonic lung | |||
| 68 (61.26) | 18 (40.0) | 35 (49.30) | 70 (46.98) | 191 (50.80) | .125* | |
| 21 (18.92) | 10 (22.22) | 13 (18.31) | 37 (24.83) | 81 (21.54) | ||
| 14 (12.61) | 8 (17.78) | 11 (15.49) | 15 (10.07) | 48 (12.77) | ||
| 8 (7.21) | 9 (20.0) | 12 (16.90) | 27 (18.12) | 56 (14.89) | ||
| Total | 111 (88.8) | 45 (100) | 71 (94.67) | 149 (96.13) | 376 (94.0) | |
n - Sample size, * the result is not significant at P < .05
Fig. 2A Multiplex PCR amplification profile of PHSSA gene (~325 bp) and Rpt2 gene (~1022 bp) of M. haemolytica serotype1 specific strains. B B. trehalosi PCR
Fig. 3A PCR amplified product agarose-gel-electrophoresis of KMT1 gene (~460 bp) specific for P. multocida. B PCR amplified product agarose-gel-electrophoresis of
The distribution of M. haemolytica serotypes
| Sample type | Isolates | Serotypes percentage | Chi-square | ||
|---|---|---|---|---|---|
| A:1 | A:2 | A:6 | |||
| Nasopharyngeal swab | 103 | 76 (73.79%) | 18 (17.48%) | 9 (8.74%) | 0.0015* |
| Pneumonic lung tissue | 88 | 81 (92.05%) | 2 (2.27%) | 5 (5.68%) | |
| Total | 191 | 157 (82.20%) | 20 (10.47%) | 14 (7.33%) | |
* The result is significant at P < .05
Antimicrobial susceptibility assay of the major bacterial pathogens of BRD
| Class | Antimicrobials | Disc conc. | Standard breakpoints | Susceptibility percentage of isolates (%) | ||
|---|---|---|---|---|---|---|
| M. H | P.M | H.S | ||||
| β-lactam | Penicillin-G | 10 U | R ≤ 28; S ≥ 29a | 56.8 | 51.9 | 48.2 |
| Ampicillin | 10 μg | R < 17; S ≥ 17b | 61.3 | 56.7 | 57.1 | |
| Fluoroquinolones | Enrofloxacin | 5 μg | R ≤ 16; S ≥ 21a | 100 | 100 | 100 |
| Ciprofloxacin | 5 μg | R < 27; S ≥ 27b | 100 | 100 | 100 | |
| Aminoglycosides | Streptomycin | 100 μg | R ≤ 11; S ≥ 15a | 21.5 | 16.0 | 28.6 |
| Gentamycin | 10 μg | R ≤ 12; S ≥ 15a | 27.2 | 19.8 | 33.9 | |
| Tetracyclin | Tetracycline | 30 μg | R < 24; S ≥ 24b | 81.7 | 77.8 | 87.5 |
| Oxytetracycline | 30 μg | R ≤ 14; S ≥ 19a | 85.3 | 83.9 | 91.1 | |
| Sulfamethoxazole-trimethoprim | 25 μg | R ≤ 10; S ≥ 16a | 100 | 100 | 100 | |
| Phenicols | Florfenicol | 30 μg | R ≤ 14; S ≥ 19a | 100 | 100 | 100 |
| Cephalosporin | Ceftiofur | 30 μg | R ≤ 17; S ≥ 21a | 100 | 100 | 100 |
M.H M. haemolytica, P.M P. multocida, H.S H. somni., Conc. Concentration
aClinical Laboratory Standard Institute (VET01S)
bThe European Committee on Antimicrobial Susceptibility testing (EU vet-CAST)
Multidrug-resistance patterns of the major bacterial pathogens associated with BRD
| Class | Antimicrobial agents | Bacterial pathogens and resistance percentage (%) | ||
|---|---|---|---|---|
| β-lactam | Penicillin-G | 43.2 | 48.1 | 51.8 |
| Ampicillin | 38.7 | 43.3 | 42.9 | |
| Aminoglycosides | Streptomycin | 78.5 | 84.0 | 71.4 |
| Gentamycin | 72.8 | 80.2 | 66.1 | |
| Tetracycline | Tetracycline | 18.3 | 22.2 | 12.5 |
| Oxytetracycline | 14.7 | 16.1 | 8.9 | |
Isolates and target gene sequences (5′ to 3′) used in PCR assay
| Isolates | Gene | Primers | Sequence (5′ to 3′) | Size (bp) | Reference |
|---|---|---|---|---|---|
| PHSSA (F) | TTC ACA TCT TCA TCC TC | 325 | [ | ||
| PHSSA (R) | TTT TCA TCC TCT TCG TC | ||||
| Rpt2 (F) | GTT TGT AAG ATA TCC CAT TT | 1022 | |||
| Rpt2 (R) | CGT TTT CCA CTT GCG TGA | ||||
| KMT1 | KMT1T7 (F) | ATC CGC TAT TTA CCC AGT GG | 460 | [ | |
| KMT1SP6(R) | GCT GTA AAC GAA CTC GCC AC | ||||
| Serogroup A | capA (F) | TGC CAA AAT CGC AGT CAG | 1044 | [ | |
| capA (R) | TTG CCA TCA TTG TCA GTG | ||||
| Serogroup B | capB (F) | CAT TTA TCC AAG CTC CAC C | 760 | [ | |
| capB (R) | GCC CGA GAG TTT CAA TCC | ||||
| Serogroup D | capD (F) | TTA CAA AAG AAA GAC TAG GAG CCC | 657 | [ | |
| capD (R) | CAT CTA CCC ACT CAA CCA TAT CAG | ||||
| Serogroup E | capE (F) | TCC GCA GAA AAT TAT TGA CTC | 511 | [ | |
| capE (R) | GCT TGC TGC TTG ATT TTG TC | ||||
| BtsodA (F) | GCC TGC GGA CAA ACG TGT TG | 144 | [ | ||
| BtsodA (R) | TTT CAA CAG AAC CAA AAT CAC GAA TG |
F forward primer, R reverse primer, bp base pair
PCR assay reaction of the current isolates
| Isolates | PCR reaction | Final extension | |||
|---|---|---|---|---|---|
| Initial denaturation | Denaturation | Annealing | Extension | ||
| 95 °C; 3 min | 95 °C; 1 min | 48 °C; 1 min | 72 °C; 1 min | 72 °C; 5 min | |
| 95 °C; 5 min | 95 °C; 1 min | 55 °C; 1 min | 72 °C; 1.5 min | 72 °C; 7 min. | |
| 95 °C; 5 min | 95 °C; 30 s | 55 °C; 30 s | 72 °C; 40 s | 72 °C; 5 min. | |